塞德斯医疗(CLDX)公司股价周一盘中出现大跌,跌幅高达5.93%,引发了市场的广泛关注。
作为一家专注于癌症免疫治疗的生物制药公司,塞德斯医疗近期公布的财报数据表现并不理想。公司2024年全年营业收入仅为702万美元,净利润则高达亏损1.58亿美元,每股收益为负2.45美元。业绩疲软或许是导致公司股价大跌的主要原因。
不过,值得关注的是,大部分机构分析师仍看好塞德斯医疗的长期发展前景。在参与评级的13家机构中,高达85%的券商给予该股买入评级,仅有15%的券商持有观望态度。分析人士认为,公司在肿瘤免疫治疗领域拥有一定的技术储备,如果能在产品上取得突破,股价未来仍有较大的上涨空间。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.